Neuro-Oncology Advances' 2026 Journal Metrics Score is 1.1, ranking Q3 in Genetics and 3 other subfields. Two-year citation average from OpenAlex data, updated August 2026.
Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.
Journal Metrics Score 2026 · 2021–2024 window citedness 1.66.
Middle 50%: 79–166 days
62 of 100 PubMed-indexed articles · 62% coverage · 2024–2025
Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.
Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.
Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.
Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.
135 of 2,062 works · same type, year & subfield
3 works · same type, year & subfield
Below field-year expectation
of 1,655 topic-associated OpenAlex sources by lifetime output
FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.67, so its typical recent paper runs about 33% below its field benchmark.
6.5% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.
Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.
OpenAlex source records · 2019–2025
2,062 OpenAlex works · 2021–2024
OpenAlex topics show the research communities this journal serves.
Candidates share at least one OpenAlex subfield (or field, if too few do) with this journal's main research topics, ignoring generic catch-all topics, and are ordered by topic overlap, then current Journal Metrics Score.
* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.
| Category | Quartile |
|---|---|
| Genetics | Q3 |
| Pulmonary and Respiratory Medicine | Q3 |
| Epidemiology | Q3 |
| Radiology, Nuclear Medicine and Imaging | Q3 |
A mid-ranked Q3 journal by citation data
By citation data, Neuro-Oncology Advances is a mid-ranked journal: it is Q3 in Genetics and 3 other subfields, the third quarter of journals by score, below the subfield median, and ranks #705 of 897 Oncology journals by Journal Metrics Score (top 79%). Neuro-Oncology Advances' 2026 Journal Metrics Score is 1.1. Recent papers took a median of 122 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $1,989 USD. OpenAlex classifies its papers in subfields including Genetics, Pulmonary and Respiratory Medicine, and Epidemiology, so check that your topic fits its scope.
Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.
Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.
Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.
OpenAlex classifies Neuro-Oncology Advances' papers in subfields including Genetics, Pulmonary and Respiratory Medicine, and Epidemiology. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.
Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.
Neuro-Oncology Advances homepage ↗Use the submit link in Neuro-Oncology Advances' author guidelines; Oxford University Press runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.
OpenAlex lists an indicative article processing charge of $1,989 USD for this open-access journal. Check the current fee, waivers, and any institutional agreement on the journal website.
Recent accepted papers took a median of 122 days from submission to acceptance, including revisions (PubMed dates). Neuro-Oncology Advances does not publish an acceptance rate.
New on PubMed
Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.
See a demo:GLP-1CRISPRLong COVID
Reviewer Two · coming soon
An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.
See what the report coversBy citation data, Neuro-Oncology Advances is a mid-ranked journal: it is Q3 in Genetics and 3 other subfields, the third quarter of journals by score, below the subfield median, and ranks #705 of 897 Oncology journals by Journal Metrics Score (top 79%). Neuro-Oncology Advances' 2026 Journal Metrics Score is 1.1. Recent papers took a median of 122 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $1,989 USD. OpenAlex classifies its papers in subfields including Genetics, Pulmonary and Respiratory Medicine, and Epidemiology, so check that your topic fits its scope.
Neuro-Oncology Advances' 2026 Journal Metrics Score is 1.1, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.
We have not found an official acceptance rate published by Neuro-Oncology Advances or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 122 days from submission to acceptance. To judge selectivity, compare Neuro-Oncology Advances' quartile and score with similar journals, or ask the editorial office.
Neuro-Oncology Advances' best quartile is Q3. By OpenAlex subfield: Q3 in Genetics; Q3 in Pulmonary and Respiratory Medicine; Q3 in Epidemiology; Q3 in Radiology, Nuclear Medicine and Imaging. Quartiles rank journals by Journal Metrics Score within each subfield.
No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Neuro-Oncology Advances will not match this score exactly. Compare journals using one source at a time.
Across 62 recent PubMed records with both dates, Neuro-Oncology Advances took a median of 122 days from submission to acceptance; the middle half took 79–166 days. This interval includes editorial handling and revisions, so it is not the time to a first decision.
OpenAlex lists an indicative article processing charge of $1,989 USD for Neuro-Oncology Advances. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.
Comparable journals include Journal of Neuro-Oncology, Neuro-Oncology, Neuro-Oncology Practice, and Brain Tumor Pathology. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.
Submit online through the link in Neuro-Oncology Advances' author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 122 days from submission to acceptance in recent PubMed records.